文献速递神经核医学肿瘤 PET/CT

11C-乙酸PET/CT显示反应性星形胶质增生在胶质瘤分类与生存预测中优于11C-甲硫氨酸PET/CT

11 C-Acetate PET/CT for Reactive Astrogliosis Outperforms 11 C-Methionine PET/CT in Glioma Classification and Survival Prediction.
PubMed 文献 · Clin Nucl Med · 2023-12-04

前瞻性研究纳入142例脑胶质瘤患者,术前行MRI、11C-甲硫氨酸(MET)PET/CT和11C-乙酸(ACE)PET/CT,计算肿瘤与本侧皮层比值(TNR_MET)及肿瘤与脉络丛比值(TNR_ACE)。结果显示11C-TNR_ACE在各胶质瘤亚型间均有显著差异,而11C-TNR_MET在少突胶质细胞瘤与IDH1野生型星形细胞瘤间无显著差异;基于11C-TNR_ACE的分类与回归树模型可区分4个风险组,其无进展生存期和总生存期差异显著。结论认为11C-ACE PET/CT在胶质瘤分类和生存预测方面优于11C-MET PET/CT。

要点

  • 11C-TNR_ACE在少突胶质细胞瘤、IDH1突变型星形细胞瘤、IDH1野生型星形细胞瘤和胶质母细胞瘤各组间均有显著差异。
  • 11C-TNR_MET在少突胶质细胞瘤与IDH1野生型星形细胞瘤之间无显著差异。
  • 基于11C-TNR_ACE的分类与回归树模型将患者分为4个风险组,中位无进展生存期分别为52.7、44.5、25.9和8.9个月。

核心结论

  • 11C-ACE PET/CT在胶质瘤分类和生存预测方面优于11C-MET PET/CT,突显其在脑胶质瘤患者中的潜在作用。

研究设计与样本

  • 前瞻性研究纳入142例脑胶质瘤患者,术前均行MRI、11C-MET PET/CT和11C-ACE PET/CT。
  • 计算11C-MET的肿瘤与本侧皮层比值(TNR_MET)和11C-ACE的肿瘤与脉络丛比值(TNR_ACE)。
  • 采用Kruskal-Wallis检验和Bonferroni事后分析比较11C-TNR_MET与11C-TNR_ACE的差异。
  • 采用Cox比例风险回归分析和分类与回归树模型评估无进展生存期(PFS)和总生存期(OS)。

主要发现

  • 少突胶质细胞瘤(ODs)、IDH1突变型星形细胞瘤、IDH1野生型星形细胞瘤和胶质母细胞瘤的中位11C-TNR_MET分别为2.75、1.40、2.30和3.70。
  • 上述四类肿瘤的中位11C-TNR_ACE分别为1.40、1.20、1.77和2.87。
  • 中位11C-TNR_MET在各组间有显著差异,但少突胶质细胞瘤与IDH1野生型星形细胞瘤之间无显著差异;中位11C-TNR_ACE在所有组间均有显著差异。
  • 分类与回归树模型识别出4个风险组:IDH1突变且11C-TNR_ACE≤1.4组、IDH1突变且11C-TNR_ACE>1.4组、IDH1野生型且11C-TNR_ACE≤1.8组、IDH1野生型且11C-TNR_ACE>1.8组,中位PFS分别为52.7、44.5、25.9和8.9个月。
  • 以IDH1突变型胶质瘤11C-TNR_ACE cutoff 1.4、IDH1野生型胶质瘤11C-TNR_ACE cutoff 2.0分组,4组中位OS分别为52.7、46.8、27.6和12.0个月;多重比较校正后4组间PFS和OS差异显著。

关键数值与推荐

  • 分类与回归树模型采用11C-TNR_ACE cutoff 1.4(IDH1突变型)和1.8(IDH1野生型)区分4个PFS风险组。
  • 生存分析采用11C-TNR_ACE cutoff 1.4(IDH1突变型)和2.0(IDH1野生型)区分4个OS风险组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 11 C-acetate (ACE) PET/CT visualizes reactive astrogliosis in tumor microenvironment. This study compared 11 C-ACE and 11 C-methionine (MET) PET/CT for glioma classification and predicting patient survival. PATIENTS AND METHODS: In this prospective study, a total of 142 patients with cerebral gliomas underwent preoperative MRI, 11 C-MET PET/CT, and 11 C-ACE PET/CT. Tumor-to-contralateral cortex (TNR MET ) and tumor-to-choroid plexus ratios (TNR ACE ) were calculated for 11 C-MET and 11 C-ACE. The Kruskal-Wallis test and Bonferroni post hoc analysis were used to compare the differences in 11 C-TNR MET and 11 C-TNR ACE . The Cox proportional hazards regression analysis and classification and regression tree models were used to assess progression-free survival (PFS) and overall survival (OS). RESULTS: The median 11 C-TNR MET and 11 C-TNR ACE for oligodendrogliomas (ODs), IDH1 -mutant astrocytomas, IDH1 -wildtype astrocytomas, and glioblastomas were 2.75, 1.40, 2.30, and 3.70, respectively, and 1.40, 1.20, 1.77, and 2.87, respectively. The median 11 C-TNR MET was significantly different among the groups, except between ODs and IDH1 -wildtype astrocytomas, whereas the median 11 C-TNR ACE was significantly different among all groups. The classification and regression tree model identified 4 risk groups ( IDH1 -mutant with 11 C-TNR ACE ≤ 1.4, IDH1 -mutant with 11 C-TNR ACE > 1.4, IDH1 -wildtype with 11 C-TNR ACE ≤ 1.8, and IDH1 -wildtype with 11 C-TNR ACE > 1.8), with median PFS of 52.7, 44.5, 25.9, and 8.9 months, respectively. Using a 11 C-TNR ACE cutoff of 1.4 for IDH1 -mutant gliomas and a 11 C-TNR ACE cutoff of 2.0 for IDH1 -wildtype gliomas, all gliomas were divided into 4 groups with median OS of 52.7, 46.8, 27.6, and 12.0 months, respectively. Significant differences in PFS and OS were observed among the 4 groups after correcting for multiple comparisons. CONCLUSIONS: 11 C-ACE PET/CT is better for glioma classification and survival prediction than 11 C-MET PET/CT, highlighting its potential role in cerebral glioma patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kim D, Yi JH, Park Y, et al. 11 C-Acetate PET/CT for Reactive Astrogliosis Outperforms 11 C-Methionine PET/CT in Glioma Classification and Survival Prediction. Clin Nucl Med. 2023. PMID: 38049976. doi:10.1097/RLU.0000000000004991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。